PRDX6 and neoplasm: Remarkably, a high tumor content of cytoplasmic peroxiredoxin 6 (PRX6) predicted better OS and DFS for lung cancer patients both by Kaplan-Meier estimates (Fig. 3b) and in univariate Cox regression analysis (Table 1), suggesting that the activation of the cytoplasmic antioxidant response protects from cancer progression.